A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian cancer treatment following its approval by NICE, AstraZeneca and MSD announced today.
The two drugs can now be used as a maintenance treatment for patients with advanced ovarian, fallopian tube, and peritoneal cancer, after complete or partial response to first-line platinum-based chemotherapy and bevacizumab, who have tested positive for homologous recombination deficiency (HRD).